{"id":27524,"date":"2024-04-09T12:45:04","date_gmt":"2024-04-09T07:15:04","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27524"},"modified":"2024-04-09T12:45:06","modified_gmt":"2024-04-09T07:15:06","slug":"p-bcma-allo1-aacr-results","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results","title":{"rendered":"Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy"},"content":{"rendered":"\n<p>P-BCMA-ALLO1 is a novel investigational BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor T-cell (CAR-T) therapy manufactured from healthy donor T-cells and available off-the-shelf. The findings presented at the AACR 2024 demonstrated that around 60% of patients (3 out of 5) with RRMM, who had advanced after receiving BCMA-targeted therapy, showed clinical improvements with P-BCMA-ALLO1. Furthermore, this investigational therapy exhibited favorable tolerability. Moreover, These latest findings further support the potential of the experimental off-the-shelf allogeneic CAR-T therapy as a viable option for a wider spectrum of multiple myeloma patients, particularly those with relapsed\/refractory disease whose cancer progressed after previous BCMA-targeted therapy\u2014a population with the most urgent medical need in this setting.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-kol-insights\"><strong>KOL insights<\/strong><strong><\/strong><\/h2>\n\n\n\n<p>&#8220;Multiple myeloma remains incurable, and patients often relapse, despite initial high response rates with BCMA-targeted immunotherapies, including autologous CAR-T therapies.\u201d<strong>\u2013Expert Opinion.<\/strong><\/p>\n\n\n\n<p>&#8220;New treatment options are urgently needed for these patients, which is why I&#8217;m encouraged by these impressive Phase 1 subgroup results, which may be the first report of an allogeneic CAR-T therapy showing clinical activity in heavily pretreated patients whose myeloma has progressed after multiple BCMA-targeted immunotherapies.&#8221; <strong>\u2013Expert Opinion.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><strong>Conclusion<\/strong><\/h2>\n\n\n\n<p>While BCMA CAR T therapies have demonstrated significant efficacy, the prospect of patients potentially discontinuing all treatments after a single CAR T infusion is highly promising. Nonetheless, access to myeloma CAR T remains restricted, and the lengthy manufacturing process hampers their utility in patients requiring immediate treatment. However, these Phase 1 subgroup findings are encouraging, possibly marking the inaugural instance of an allogeneic CAR-T therapy exhibiting clinical efficacy in heavily treated patients with progressive myeloma following multiple BCMA-targeted immunotherapies. Apart from that, the company is actively investigating the most effective lymphodepletion regimen for CAR-T therapy in solid tumors and is leveraging these insights directly into the P-MUC1C-ALLO1 trial. The aim is to replicate the success observed in myeloma for solid tumors. <strong>Lastly, the company anticipates sharing comprehensive datasets on both the BCMA and MUC1-C programs in the second half of 2024.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>P-BCMA-ALLO1 is a novel investigational BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor T-cell (CAR-T) therapy manufactured from healthy donor T-cells and available off-the-shelf. The findings presented at the AACR 2024 demonstrated that around 60% of patients (3 out of 5) with RRMM, who had advanced after receiving BCMA-targeted therapy, showed clinical improvements [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":27525,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[3057,22035,20587],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-27524","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-aacr","tag-aacr-2024","tag-aacr-conference","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Positive Results of P-BCMA-ALLO1 | AACR 2024<\/title>\n<meta name=\"description\" content=\"Findings presented at AACR 2024 demonstrated that around 60% of patients with RRMM, showed clinical improvements with P-BCMA-ALLO1.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Positive Results of P-BCMA-ALLO1 | AACR 2024\" \/>\n<meta property=\"og:description\" content=\"Findings presented at AACR 2024 demonstrated that around 60% of patients with RRMM, showed clinical improvements with P-BCMA-ALLO1.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-09T07:15:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-09T07:15:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09124315\/p-bcma-allo1-aacr-results.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Positive Results of P-BCMA-ALLO1 | AACR 2024","description":"Findings presented at AACR 2024 demonstrated that around 60% of patients with RRMM, showed clinical improvements with P-BCMA-ALLO1.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results","og_locale":"en_US","og_type":"article","og_title":"Positive Results of P-BCMA-ALLO1 | AACR 2024","og_description":"Findings presented at AACR 2024 demonstrated that around 60% of patients with RRMM, showed clinical improvements with P-BCMA-ALLO1.","og_url":"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-04-09T07:15:04+00:00","article_modified_time":"2024-04-09T07:15:06+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09124315\/p-bcma-allo1-aacr-results.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results","url":"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results","name":"Positive Results of P-BCMA-ALLO1 | AACR 2024","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09124315\/p-bcma-allo1-aacr-results.png","datePublished":"2024-04-09T07:15:04+00:00","dateModified":"2024-04-09T07:15:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Findings presented at AACR 2024 demonstrated that around 60% of patients with RRMM, showed clinical improvements with P-BCMA-ALLO1.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/p-bcma-allo1-aacr-results#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09124315\/p-bcma-allo1-aacr-results.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09124315\/p-bcma-allo1-aacr-results.png","width":466,"height":284,"caption":"p-bcma-allo1-aacr-results"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09124315\/p-bcma-allo1-aacr-results-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR Conference<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AACR<\/span>","<span class=\"advgb-post-tax-term\">AACR 2024<\/span>","<span class=\"advgb-post-tax-term\">AACR Conference<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 9, 2024","modified":"Updated on Apr 9, 2024"},"absolute_dates_time":{"created":"Posted on Apr 9, 2024 12:45 pm","modified":"Updated on Apr 9, 2024 12:45 pm"},"featured_img_caption":"p-bcma-allo1-aacr-results","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27524"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27524\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27525"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27524"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27524"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}